Department of Public Health, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India
*Corresponding Author: Debraj Mukhopadhyay, Department of Public Health, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India.
Received: October 08, 2020; Published: November 18, 2020
A novel coronavirus (COVID-19) was spread in the world like a pandemic, in late December 2019. There were challenges for treatment interventions as well as types of medicines. Despite there is no specific therapy strategy for COVID-19, studies have identified Hydroxychloroquine (HCQ) and Remdesivir as the most widely used medicine worldwide [1-3]. So, this letter was written to synthesize the evidence and outcomes of the medicines for COVID-19 patients.
Citation: Debraj Mukhopadhyay. “Hydroxychloroquine or Remdesivir to Treat COVID-19 Patients". Acta Scientific Pharmaceutical Sciences 4.12 (2020): 47-49.
Copyright: © 2020 Debraj Mukhopadhyay. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.